Bedside Evaluation of Coagulation in Children With Congenital Heart Disease (POCHEMO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02387944|
Recruitment Status : Completed
First Posted : March 13, 2015
Last Update Posted : January 26, 2018
The purpose of this study is to assess coagulation and platelet function in children with congenital heart disease, measured with a bedside device (thromboelastometry and impedance aggregometry).
The investigators also aim to determine if this device detect post-cardiopulmonary bypass clotting derangements and may help to manage bleeding in this population.
|Condition or disease|
|Congenital Heart Defect Blood Coagulation Disorder|
Hemostasis, a main concern during and after any surgical procedure, is traditionally monitored by the following laboratory tests: activated Partial Thrombin Time (aPTT), prothrombin time (PT), fibrinogen, platelets count. They neither provide a reliable estimate of the risk of bleeding, nor allow determining useful interventions.
New investigations of hemostasis are now used and validated during and after surgery: Rotational Thromboelastometry (ROTEM®) and impedance aggregometry. This is a quick bedside functional analysis of the patient's clotting. Children who undergo surgery under cardiopulmonary bypass (CPB) are particularly at risk of bleeding and this population hasn't been studied with large cohort yet.
Hypothesis: Hemostasis in children with CHD, especially when cyanotic, is intrinsically abnormal. The corrective surgery on CPB induces further hemostatic disorders which can be identified by the ROTEM platelet®.
The aim of the study is to evaluate the hemostatic function of the child with congenital heart disease using a Point-Of-Care (platelet-ROTEM ®) system, before surgery and after alterations induced by cardiopulmonary bypass (CPB).
This is a single center, observational, prospective study. Expected duration: 2 years. The investigators plan to include 200 patients with CHD, 100 patients undergoing surgery with CPB and 100 patients with congenital heart disease requiring cardiac catheterization. Recruitment will be conducted by the Division of Paediatric Cardiology.
Inclusion criteria include an age of 0-16 years and a diagnosis of congenital heart disease requiring surgery with CPB or cardiac catheterization. Patients with known dyscrasia or treated with antiaggregant within 10 days/oral anticoagulants within 48h before surgery/catheterization.
ROTEM platelet® test will be performed before surgery/catheterization. Patients undergoing surgery will have a second test within 30 minutes after the end of cardiopulmonary bypass. All patients will benefit from the usual cares.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||"Point-Of-Care" Evaluation of Hemostasis in Children With Congenital Heart Disease|
|Study Start Date :||March 2015|
|Actual Primary Completion Date :||July 6, 2017|
|Actual Study Completion Date :||July 7, 2017|
Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
Children with congenital heart defect undergoing cardiac catheterism
- Hemostasis measured by thromboelastometry and impedance aggregometry [ Time Frame: Single measurement, during general anesthesia, immediately before procedure, when arterial line available ]
- Hemostasis measured by thromboelastometry and impedance aggregometry in cyanotic children [ Time Frame: Single measurement, during general anesthesia, immediately before procedure, when arterial line available ]
- Thromboelastometry and impedance aggregometry changes after cardiopulmonary bypass (CPB) [ Time Frame: maximum 3 measurements, during surgery and up to 6 hours after end of CBP ]
- Thromboelastometry and impedance aggregometry changes in children with significant bleeding after CPB [ Time Frame: Single measurement, during general anesthesia, immediately before procedure, when arterial line available ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387944
|PICU, Centre Hospitalier Universitaire Vaudois|
|Lausanne, Vaud, Switzerland, 1011|
|Principal Investigator:||Stefano Di Bernardo, MD||CHUV|